Agensys, Inc.

Facet Biotech Corporation

Genentech, Inc.

The Cleveland Clinic Foundation

Abbvie Biotherapeutics Inc.

Pdl Biopharma, Inc.

Abbott Biotherapeutics Corp.

Urogenesys, Inc.

Dana-farber-cancer Institute Inc.

Abbvie Inc.

Daniel E Afar

Rene S Hubert

Arthur B Raitano

Douglas C Saffran

Kahan Leong

Stephen Chappell Mitchell

Aya Jakobovits

Vinay Bhaskar

David Powers

Vanitha Ramakrishnan

Ingrid W Caras

Debbie Law

Richard Murray

Agustin De La Calle

Pia M Challita-Eid

Mary Faris

Wangmao Ge

Steven Chappell Mitchell

Robert Kendall Morrison

Kenneth Carl Anderson

Jieyi Wang

Christian B Allan

Edward B Reilly

Karen J Morrison

Louie Naumovski

Elana Levin

Yu-Tzu Tai

Eric Hsi

Mark G Anderson

Kenneth C Andersen

Ingrid Caras

Uses of anti-CS1 antibodies, alone or in combination with other agents, for the treatment of rare lymphomas, such as NK lymphomas, NK/T-cell lymphomas, and angioimmunoblastic lymphomas.

Use of anti-CS1 antibodies for treatment of rare lymphomas

Described is a novel family of cell surface serpentine transmembrane antigens. Two of the proteins in this family are exclusively or predominantly expressed in the prostate, as well as in prostate cancer, and thus members of this family have been termed 'STEAP' (Six Transmembrane Epithelial Antigens of the Prostate). Four particular human STEAPs are described and characterized herein. The prototype member of the STEAP family, STEAP-1, appears to be a type IIIa membrane protein expressed predominantly in prostate cells in normal human tissues. Structurally, STEAP-1 is a 339 amino acid protein characterized by a molecular topology of six transmembrane domains and intracellular N- and C-termini, suggesting that it folds in a 'serpentine' manner into three extracellular and two intracellular loops. STEAP-1 protein expression is maintained at high levels across various stages of prostate cancer. Moreover, STEAP-1 is highly over-expressed in certain other human cancers.

Serpentine transmembrane antigens expressed in human cancers and uses thereof

A novel prostate tumor associated gene (designated 24P4C12) and its encoded protein is described. 24P4C12 is highly expressed in prostate tissue xenografts, providing evidence that it is turned on in at least some prostate cancers. 24P4C12 provides a diagnostic and/or therapeutic target for prostate and other cancers.

13-transmembrane protein expressed in prostate cancer

The invention relates to the identification and generation of antibodies that bind to TMEFF2 proteins which are involved in cancer. Further, the invention provides for the use of these antibodies in the treatment of cancer.

Antibodies against cancer antigen TMEFF2 and uses thereof

A novel gene (designated 85P1B3) and its encoded protein are described. While 85P1B3 exhibits tissue specific expression in normal adult tissue, it is aberrantly expressed in multiple cancers including set forth in Table 1. Consequently, 85P1B3 provides a diagnostic and/or therapeutic target for cancers. The 85P1B3 gene or fragment thereof, or its encoded protein or a fragment thereof, can be used to elicit an immune response.

Nucleic acid and corresponding protein entitled 85P1B3 useful in treatment and detection of cancer

Described is a novel family of cell surface serpentine transmembrane antigens. Two of the proteins in this family are exclusively or predominantly expressed in the prostate, as well as in prostate cancer, and thus members of this family have been termed 'STEAP' (Six Transmembrane Epithelial Antigen of the Prostate). Four particular human STEAPs are described and characterized herein. The human STEAPs exhibit a high degree of structural conservation among them but show no significant structural homology to any known human proteins. The prototype member of the STEAP family, STEAP-1, appears to be a type IIIa membrane protein expressed predominantly in prostate cells in normal human tissues. Structurally, STEAP-1 is a 339 amino acid protein characterized by a molecular topology of six transmembrane domains and intracellular N- and C-termini, suggesting that it folds in a 'serpentine' manner into three extracellular and two intracellular loops. STEAP-1 protein expression is maintained at high levels across various stages of prostate cancer. Moreover, STEAP-1 is highly over-expressed in certain other human cancers.

Serpentine transmembrane antigens expressed in human cancers and uses therefor

Described is a novel gene and its encoded secreted tumor antigen, termed BPC-1, and to diagnostic and therapeutic methods and compositions useful in the management of various cancers which express BPC-1, particularly including prostate cancer and bladder cancer. In human normal tissues, BPC-1 is only expressed in certain tissues of the brain. However, BPC-1 is expressed at high levels in prostate cancer cells and is also expressed in bladder cancer cells. The structure of BPC-1 includes a signal sequence and a CUB domain. BPC-1 protein is secreted. Preliminary experimental evidence suggests that BPC-1 is directly involved in oncogenesis or maintenance of the transformed phenotype of cancer cells expressing BPC-1. BPC-1 also appears to bind specifically to a cellular protein expressed in prostate cancer cells and other cells.

BPC-1: a secreted brain-specific protein expressed and secreted by prostate and bladder cancer cells

The present disclosure provides methods for treating multiple myeloma comprising administering to a subject with multiple myeloma the anti-CS1 antibody HuLuc63 in combination with dexamethasone and, optionally, thalidomide.

Compositions and methods using anti-CS1 antibodies to treat multiple myeloma

Described herein are methods and compositions that can be used for diagnosis and treatment of cancer.

A novel testis-specific gene expressed in human prostate cancer, designated 22P4F11, is described. Analysis of 22P4F11 mRNA expression in normal prostate, prostate tumor xenografts, and a variety of normal tissues indicates that the expression of this gene is testis specific in normal tissues. The 22P4F11 gene is also expressed in human prostate tumors, in some cases at high levels. A full length cDNA encoding 22P4F11 is provided. The 22P4F11 transcript and/or protein may represent a useful diagnostic marker and/or therapeutic target for prostate cancer.

Gene expressed in prostate cancer

Described is a family of cell surface serpentine transmembrane antigens. Two of the proteins in this family are expressed in the prostate, as well as in prostate cancer, and thus members of this family have been termed 'STEAP' (ixransmembranepithelialntigen of therostate). Four particular human STEAPs are described and characterized herein. The human STEAPs exhibit a high degree of structural conservation among them but show no significant structural homology to any known human proteins. The prototype member of the STEAP family is STEAP-1, which appears to be a type IIIa membrane protein. STEAP-1 is a 339 amino acid protein. STEAP-1 protein expression is maintained at high levels across various stages of prostate cancer. Moreover, STEAP-1 is highly over-expressed in certain other human cancers.

Growing community of inventors

Pacific Palisades, CA, United States of America

Daniel E Afar